Merck (MRK GY) to buy Silence Therapeutics for USD 20/ADS in cash

Merck (MRK GY) to buy Silence Therapeutics for USD 20/ADS in cash.

All-cash acquisitions of listed biotechs sit in the cleaner end of the M&A playbook: with no stock component and no CVR attached, the target's spread to the offer price collapses to pure completion risk rather than valuation risk on the acquirer's paper. The usual sequence is a gap toward the offer, then a residual arb spread that prices the timeline to close and the probability of regulatory or antitrust friction, with cross-border biotech deals historically drawing the longer reviews. One point worth flagging: the ticker MRK GY denotes the German Merck KGaA, a separate company from the US Merck & Co despite the tagging, and the two names trade and consolidate on entirely different balance sheets. For the target, the USD-denominated ADS offer fixes consideration in dollars, so any spread expressed in the underlying London line carries an FX leg on top of deal risk. The follow-ons are the premium versus the prior close, the expected closing window, any competing-bid speculation typical of platform-technology biotechs, and whether the acquirer frames this as bolt-on pipeline fill-in, the pattern large pharma has repeated through repeated episodes of patent-cliff-driven buying.